Low-dose renin inhibitor and low-dose AT1-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes
| Autor: | David Louis Feldman, Wolfgang Derer, Silke Meiners, Bernhard Pilz, Ralf Dechend, Anette Fiebeler, Erdenechimeg Shagdarsuren, Petra Gratze, Dominik N. Müller, Randy L. Webb |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Medicine (General)
medicine.medical_specialty Angiotensin receptor medicine.drug_class Angiotensinogen 030204 cardiovascular system & hematology Pharmacology Renin inhibitor Receptor Angiotensin Type 1 Animals Genetically Modified Renin-Angiotensin System 03 medical and health sciences chemistry.chemical_compound R5-920 0302 clinical medicine Endocrinology Fumarates Internal medicine Renin Renin–angiotensin system Internal Medicine medicine Animals Humans Receptor Antihypertensive Agents Angiotensin II receptor type 1 business.industry Aliskiren Amides Angiotensin II Rats Losartan chemistry Hypertension business medicine.drug |
| Zdroj: | Journal of the Renin-Angiotensin-Aldosterone System, Vol 8 (2007) |
| ISSN: | 1752-8976 1470-3203 |
| DOI: | 10.3317/jraas.2007.008 |
| Popis: | We studied the effects of extremely low-dose human renin inhibition (aliskiren) with low angiotensin II receptor blockade (losartan) in a novel double-transgenic rat model harbouring both human renin and angiotensinogen genes. We found that low-dose aliskiren and low-dose losartan effectively reduced mortality and target-organ damage with minimal, non-significant, effects on blood pressure (BP). Our data suggest that renin-angiotensin system (RAS) inhibition ameliorates target-organ damage in an Ang II-driven model of hypertension. Direct renin inhibition is equally efficacious in this regard. Our study does not fully answer the question of BP-lowering versus RAS inhibition. This question is important and was at least partially addressed with our low-dose model. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|